| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10195159 | JAZZ PHARMS RES | Processes and apparatus for extraction of active substances and enriched extracts from natural products |
May, 2022
(1 year, 11 months ago) | |
| US11096905 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Oct, 2035
(11 years from now) | |
| US11207292 | JAZZ PHARMS RES | Cannabidiol preparations and its uses |
Apr, 2039
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9956185 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US11311498 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US10137095 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US10603288 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US10709671 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US11766411 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US10709673 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US9956183 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US9956184 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US11154516 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US11633369 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US11357741 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US11446258 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US10111840 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US10849860 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US11701330 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US10709674 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US10966939 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US9956186 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US10092525 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US9949937 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US11400055 | JAZZ PHARMS RES | Use of cannabidiol in the treatment of epilepsy |
Oct, 2035
(11 years from now) | |
| US11065209 | JAZZ PHARMS RES | Use of cannabidiol in the treatment of epilepsy |
Oct, 2035
(11 years from now) | |
| US10918608 | JAZZ PHARMS RES | Use of cannabidiol in the treatment of epilepsy |
Oct, 2035
(11 years from now) | |
| US11160795 | JAZZ PHARMS RES | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
Mar, 2041
(16 years from now) | |
| US11406623 | JAZZ PHARMS RES | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
Mar, 2041
(16 years from now) | |
Epidiolex is owned by Jazz Pharms Res.
Epidiolex contains Cannabidiol.
Epidiolex has a total of 29 drug patents out of which 1 drug patent has expired.
Expired drug patents of Epidiolex are:
- US10195159
Epidiolex was authorised for market use on 28 September, 2018.
Epidiolex is available in solution;oral dosage forms.
Epidiolex can be used as use in combination with clobazam for the treatment of seizures in patients with dravet syndrome, use in combination with clobazam for treatment of drop seizures in patients with lennox gastaut syndrome, use for the treatment of seizures in patients with dravet syndrome, use for the treatment of seizures in patients with lennox-gastaut syndrome, use for the treatment of convulsive seizures in patients with dravet syndrome, use for reducing convulsive seizure frequency in patients with dravet syndrome, use for the treatment of drop seizures in patients with dravet syndrome, use for the treatment of seizures associated with lennox-gastaut syndrome, use for reducing seizure frequency in patients with tuberous sclerosis complex, use in combination with clobazam for the treatment of seizures in patients with dravet syndrome who have been previously treated with clobazam, use for the treatment of seizures in patients with tuberous sclerosis complex, use for the treatment of focal seizures in patients with dravet syndrome, use for the treatment of atonic seizures in patients with lennox-gastaut syndrome, use in combination with clobazam for treatment of seizures in patients with lennox gastaut syndrome, use for the treatment of seizures associated with tuberous sclerosis complex in patients taking everolimus, use for the treatment of drop seizures in patients with lennox-gastaut syndrome, use for the treatment of convulsive seizures in patients with lennox gastaut syndrome, use for the treatment of absence seizures in patients with lennox-gastaut syndrome.
Drug patent challenges can be filed against Epidiolex from 28 September, 2022.
The generics of Epidiolex are possible to be released after 01 March, 2041.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-216) | Sep 28, 2025 |
| Orphan Drug Exclusivity(ODE-332) | Jul 31, 2027 |
| Orphan Drug Exclusivity(ODE-326) | Jul 31, 2027 |
| M(M-270) | Oct 20, 2026 |
| New Chemical Entity Exclusivity(NCE) | Sep 28, 2023 |
| New Patient Population(NPP) | Jul 31, 2023 |
Drugs and Companies using CANNABIDIOL ingredient
NCE-1 date: 28 September, 2022
Market Authorisation Date: 28 September, 2018
Treatment: Use for the treatment of convulsive seizures in patients with dravet syndrome; Use for the treatment of absence seizures in patients with lennox-gastaut syndrome; Use in combination with clobazam for ...
Dosage: SOLUTION;ORAL
EPIDIOLEX family patents
